NCT05989295 is a NA clinical trial of probiotic LRa05 in Atopic Skin, sponsored by Wecare Probiotics Co., Ltd..

Who is sponsoring NCT05989295?

NCT05989295 is sponsored by Wecare Probiotics Co., Ltd..

What drugs are being tested in NCT05989295?

Interventions in NCT05989295: probiotic LRa05.

What condition does NCT05989295 study?

NCT05989295 studies Atopic Skin, Children.

Is NCT05989295 still recruiting?

NCT05989295 is currently completed. Last updated 14 August 2023.

Last reviewed 2023-08-14 · How we verify

NCT05989295

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Probiotic That Reduces Atopic Skin

Completed NA Last updated 14 August 2023

What this trial tests

NA trial testing probiotic LRa05 in Atopic Skin in 32 participants. Completed in 21 April 2023.

Timeline

26 January 2022

Primary endpoint
1 December 2022

21 April 2023

Quick facts

Lead sponsor	Wecare Probiotics Co., Ltd.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	health services research
Enrollment	32
Start date	26 January 2022
Primary completion	1 December 2022
Estimated completion	21 April 2023
Sites	2 locations across Spain

Drugs / interventions tested

probiotic LRa05

Conditions studied

Atopic Skin — all drugs for Atopic Skin →
Children — all drugs for Children →

Sponsor

Wecare Probiotics Co., Ltd. — full company profile →

Who can join

Adults 2 to 14, any sex, with Atopic Skin or Children. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To assess the efficacy and safety of the use of probiotics as food supplements in reducing the SCORAD index in children with atopic skin compared with placebo. This is a randomized, placebo-controlled, double-blind clinical trial with 2 parallel groups, which will include 32 patients who attend some of the research centers. Patients will be randomized into one of the 2 study groups (allocation ratio 1: 1): Experimental group (Lactobacillus rhamnosus LRa05) and placebo group (placebo). The reduction of the SCORAD index, the number of sprouts in 12 weeks, the days of use of topical corticosteroids and one valuations of the skin condition (hydration).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Wecare Probiotics Co., Ltd. trials

Trials by the same sponsor.

NCT07529457 — Akk09 in Adults With Constipation · NA · not yet recruiting
NCT07507955 — Probiotics for Constipation Relief in Adults · NA · not yet recruiting
NCT07462494 — Probiotic Intervention in Constipation · NA · not yet recruiting
NCT07462481 — Probiotic Improve Constipation · NA · recruiting
NCT07507929 — Probiotic for Weight Management in Overweight and Obese Adults · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05989295 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Wecare Probiotics Co., Ltd.
Last refreshed: 14 August 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05989295.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing